Board of directors (12)
Directors with a Section 16 filing in the last 13 months. “Since” is the first filing as a director; SEC data sets start in 2016.
Executive officers (13)
Company facts
- Chair
- Thomas E. Polen, Jr.
- In S&P 500 since
- Sep 1972
- Incorporated in
- NJ
- Fiscal year ends
- September
- SEC industry
- Surgical & Medical Instruments & Apparatus
- SEC filings
- EDGAR
Connections to other S&P 500 companies
Current directors and officers who also hold a role at another S&P 500 company.
Major holders (5% or more)
Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.
No 5% holder filings parsed yet for this company.
Insider trades
Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 76 | $198.13 | $15K |
| Sep 28, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 76 | $183.70 | $14K |
| Aug 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 165 | $188.49 | $31K |
| Aug 13, 2026 | Thomas E. Polen, Jr. Chairman, CEO and President | Sale | 4,152 | $185.00 | $768K |
| Aug 11, 2026 | Roland Goette EVP and President, EMEA | Sale | 2,438 | $180.84 | $441K |
| Jul 27, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 75 | $157.13 | $12K |
| Jun 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 75 | $152.80 | $11K |
| Jun 24, 2026 | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $145.66 | $160K |
| Jun 10, 2026 | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Sale | 1,100 | $151.48 | $167K |
| Jun 1, 2026 | Thomas E. Polen, Jr. Chairman, CEO and President | Sale | 2,764 | $146.35 | $405K |
| May 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 75 | $147.35 | $11K |
| Apr 27, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 74 | $151.94 | $11K |
| Mar 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 75 | $156.83 | $12K |
| Feb 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 75 | $181.84 | $14K |
| Feb 18, 2026 | Bertram L. Scott Director | Sale | 953 | $182.61 | $174K |
| Jan 26, 2026 | Michael Feld EVP, Chief Revenue Officer | Sale | 75 | $202.73 | $15K |
| Jan 15, 2026 | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Sale | 1,010 | $206.54 | $209K |
| Jan 15, 2026 | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Sale | 600 | $209.00 | $125K |
| Dec 26, 2025 | Michael Feld EVP, Chief Revenue Officer | Sale | 74 | $196.08 | $15K |
| Dec 17, 2025 | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | Sale | 629 | $196.03 | $123K |
| Dec 1, 2025 | Michael Feld EVP, Chief Revenue Officer | Sale | 75 | $193.36 | $15K |
| Nov 7, 2025 | Bertram L. Scott Director | Sale | 217 | $176.58 | $38K |
| Oct 27, 2025 | Michael Feld EVP, Chief Revenue Officer | Sale | 57 | $186.01 | $11K |
| Sep 26, 2025 | Michael Feld EVP, Chief Revenue Officer | Sale | 58 | $181.03 | $10K |
| Sep 10, 2025 | Claire Fraser Director | Sale | 917 | $187.50 | $172K |
Board and executive changes
Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.
- Jul 22, 2026
On July 19, 2026, Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Dr. Garrison will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next President of the Medical Essentials segment. Going forward, to streamline BD's operating model, the BioPharma Systems segment will report directly to Thomas E. Polen, Chairman, CEO and President of BD.
Read the 8-K filing - May 7, 2026
of Becton, Dickinson and Company’s (the “Company”) Current Report on Form 8-K filed with the Securities and Exchange Commission on October 15, 2025 (the “Original Form 8-K”). This Amendment should be read in conjunction with the Original 8-K.
Read the 8-K filing - Apr 9, 2026
On April 6, 2026, Richard E. Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Mr. Byrd will remain in his role through June. BD intends to name a successor to Mr. Byrd prior to his retirement date.
Read the 8-K filing - Feb 9, 2026
In connection with the completion of the Transactions, and effective as of the Closing, Claire M. Fraser, Ph.D., resigned as a director of the Company and was appointed to the Waters board of directors. As a result of Dr. Fraser’s resignation, the size of the board of directors of the Company was reduced to twelve directors. The board of directors of the Company currently consists of William M. Brown, Carrie L. Byington, R. Andrew Eckert, Gregory J. Hayes, Jeffrey W. Henderson, Robert L. Huffines, Christopher Jones, Thomas E. Polen, Timothy M. Ring, Bertram L. Scott, Joanne Waldstreicher and Jacqueline Wright.
Read the 8-K filing - Jan 30, 2026
Executive Officer Severance Plan On January 27, 2026, the Board of Directors of Becton, Dickinson and Company (“BD”) approved and adopted the BD Executive Severance Plan (the “Severance Plan”), effective January 27, 2026. The Severance Plan provides severance benefits to management employees designated at job level J-G9 (including the Company’s named executive officers and executive officers) upon a termination of their employment by the Company without Cause (as defined in the Severance Plan), other than due to death or disability, and who execute and do not revoke a general release of claims.
Read the 8-K filing - Dec 1, 2025
DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. In connection with their appointments to the Board, effective December 1, 2025, Mr. Huffines and Ms. Wright will each receive restricted stock units valued at $33,575, representing a prorated grant from the effective date of their election to the Board through BD’s 2026 Annual Meeting of Shareholders. Information regarding the compensation of the non-management members of the Board is included under the caption “Non-Management Director Compensation” in BD’s proxy statement relating to its 2025 Annual Meeting of Shareholders.
Read the 8-K filing - Nov 17, 2025
DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On November 17, 2025, Robert L. Huffines and Jacqueline Wright were elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”), effective December 1, 2025. At that time, the size of the Board will expand from twelve to fourteen members. Upon joining the Board, Ms. Wright will serve as a member of both the Audit Committee and the Compensation and Human Capital Committee of the Board and Mr. Huffines will serve as a member of both the Audit Committee and the Corporate Governance and Nominating Committee of the Board. BD’s Board has determined that each of Ms. Wright and Mr. Huffines is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD’s Statement of Corporate Governance Principles.
Read the 8-K filing - Oct 15, 2025
DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On October 9, 2025, Christopher J. DelOrefice informed Becton, Dickinson and Company (the “Company” or “BD”) of his intention to resign from his position as the Company’s Executive Vice President and Chief Financial Officer effective December 5, 2025 to pursue a new professional opportunity. Mr. DelOrefice will remain in his current role with the Company until his departure. Mr. DelOrefice’s departure is not the result of any disagreement with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices. In connection with Mr.
Read the 8-K filing - Mar 27, 2025
Effective March 26, 2025, Gregory J. Hayes was elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”). At that time, the size of the Board was expanded from eleven to twelve members. Upon joining the Board, Mr. Hayes will serve as a member of both the Audit Committee and the Compensation and Human Capital Committee of the Board. BD’s Board has determined that Mr. Hayes is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD’s Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of the Board is included under the caption “Non-Management Director Compensation” in BD’s proxy statement relating to its 2025 Annual Meeting of Shareholders. In connection with his appointment, Mr.
Read the 8-K filing - Jan 10, 2025
On January 9, 2025, the Board of Directors (the “Board”) of Becton, Dickinson and Company (the “Company”) appointed Pamela L. Spikner as Senior Vice President, Chief Accounting Officer and Controller, effective January 20, 2025. Christopher DelOrefice, Executive Vice President and Chief Financial Officer, will continue to serve as interim principal accounting officer until the Company files its Form 10-Q for the quarter ended December 31, 2024. Thereafter, Ms. Spikner will serve as the Company’s principal accounting officer. Prior to joining the Company, Ms. Spikner, age 48, served as Chief Accounting Officer of R1 RCM since July 2021. Ms. Spikner also previously was Assistant Corporate Controller of Hill-Rom Holdings, Inc., a medical technology provider, from July 2019 to July 2021. Ms.
Read the 8-K filing - Aug 30, 2024
Effective August 30th, the following leadership change will take place. Thomas Spoerel will serve as the Senior Vice President, CFO Regions along with finance leadership for the finance integration of the recently announced agreement for Becton Dickinson to acquire the Edwards Life Sciences’ Critical Care product group. Tom will no longer serve as the Company’s principal accounting officer as set forth under Section 16 of the Securities Exchange Act of 1934, as amended, and Christopher DelOrefice, Executive Vice President and Chief Financial Officer, will assume the responsibilities of principal accounting officer on an interim basis.
Read the 8-K filing - Feb 27, 2024
On February 22, 2024, David Hickey, Executive Vice President and President of the Life Sciences segment of Becton, Dickinson and Company ("BD"), informed BD of his intention to retire, effective July 1, 2024. BD intends to name a successor to Mr. Hickey prior to his retirement date.
Read the 8-K filing - Nov 27, 2023
On November 21, 2023, the Board of Directors (the "Board") of Becton, Dickinson and Company (the “Company”) adopted a policy (the "Policy") that the Company will not enter into any new employment, severance or separation agreement with an executive officer (as defined in the Policy), or establish any new plan or policy covering an executive officer, that provides for cash severance benefits (as defined in the Policy) exceeding 2.99 times the sum of the executive officer’s base salary plus target annual bonus, without seeking stockholder ratification of such agreement, plan or policy. The foregoing description of the Policy is qualified in its entirety by reference to the actual text of the Executive Officer Cash Severance Policy, which is attached hereto as Exhibit 10.1.
Read the 8-K filing - Jul 24, 2023
On July 24, 2023, Dr. Joanne Waldstreicher was elected to the Board of Directors of Becton, Dickinson and Company (“BD”). Upon joining BD’s Board of Directors, Dr. Waldstreicher will serve as a member of both the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board. BD’s Board of Directors has determined that Dr. Waldstreicher is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD’s Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD’s Board of Directors is included under the caption “Non-Management Director Compensation” in BD’s proxy statement relating to its 2023 Annual Meeting of Shareholders. In connection with her appointment, Dr.
Read the 8-K filing - Jan 30, 2023
At the 2023 Annual Meeting of Shareholders (the "2023 Annual Meeting") of Becton, Dickinson and Company ("BD") held on January 24, 2023, BD's shareholders approved amendments to BD's 2004 Employee and Director Equity-Based Compensation Plan (the "2004 Plan") to 1) extend the term of the 2004 Plan to January 25, 2033, and 2) increase the number of shares available for awards under the 2004 Plan by 5,700,000 shares. A description of the terms of the 2004 Plan, as so amended, is contained under the caption "Proposal 5. Approval of amendments to 2004 employee and director equity-based compensation plan" in BD's proxy statement relating to the 2023 Annual Meeting. A copy of the 2004 Plan, as so amended, is attached hereto as Exhibit 10.1.
Read the 8-K filing
Show 23 older changes
- Jan 6, 2023
On December 30, 2022, Samrat S. Khichi, Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel, informed BD of his intent to depart BD for a new opportunity, effective February 3, 2023.
Read the 8-K filing - Aug 25, 2022
On August 25, 2022, Becton, Dickinson and Company ("BD") announced the appointment of two senior leaders to segment president roles. Michael Garrison has been named BD's Executive Vice President and President, Medical Segment, and Richard Byrd has been named BD's Executive Vice President and President, Interventional Segment, both effective September 6, 2022. In addition, on August 22, 2022, Simon Campion informed BD that he will depart BD on September 9, 2022 for an executive role in the health care industry. Mr. Campion joined BD through the acquisition of C.R. Bard, Inc. and most recently served as BD's Executive Vice President and President, Medical Segment.
Read the 8-K filing - Apr 6, 2022
Resignation of Directors In connection with the separation of Becton, Dickinson and Company’s (“BD”) diabetes care business (the “Separation”) through the distribution of 100% of the outstanding shares of common stock, par value $0.01 per share, of Embecta Corp. (“embecta”) to BD’s stockholders of record as of the close of business on March 22, 2022 (the “Distribution”), each of Claire Pomeroy, MD and David F. Melcher has resigned as directors of BD, in each case effective as of April 1, 2022, in connection with the completion of the Separation and the Distribution and their appointment to the board of directors of embecta. Composition of the BD Board Effective at the time of the Separation and the Distribution, the size of the board of directors of BD has been reduced to eleven directors. The board of directors of BD currently consists of William M. Brown, Catherine M.
Read the 8-K filing - Mar 31, 2022
On March 28, 2022, Alberto Mas, Executive Vice President and President of the Medical segment of BD informed BD of his intention to retire, effective at the end of BD’s fiscal year on September 30, 2022. BD intends to name a successor to Mr. Mas prior to his retirement date. To support a successful succession process, Mr. Mas will be paid a one-time cash retention award of $300,000, contingent upon his continuing active employment through September 30, 2022.
Read the 8-K filing - Mar 1, 2022
On February 28, 2022, William M. Brown was elected to the Board of Directors of Becton, Dickinson and Company (“BD”). Upon joining BD’s Board of Directors, Mr. Brown will serve as a member of both the Compensation and Human Capital Committee and the Corporate Governance and Nominating Committee of the Board. BD’s Board of Directors has determined that Mr. Brown is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD’s Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD’s Board of Directors is included under the caption “Non-Management Director Compensation” in BD’s proxy statement relating to its 2022 Annual Meeting of Shareholders. In connection with his appointment, Mr.
Read the 8-K filing - Oct 22, 2021
On October 21, 2021, Carrie L. Byington, M.D. was elected to the Board of Directors of Becton, Dickinson and Company (“BD”). Upon joining BD’s Board of Directors, Dr. Byington will serve as a member of both the Audit Committee and the Quality and Regulatory Committee of the Board. BD’s Board of Directors has determined that Dr. Byington is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD’s Statement of Corporate Governance Principles. Information regarding the compensation of the non-management members of BD’s Board of Directors is included under the caption “Non-Management Directors’ Compensation” in BD’s proxy statement relating to its 2021 Annual Meeting of Shareholders. In connection with her appointment, Dr.
Read the 8-K filing - Aug 30, 2021
This Amendment No. 1 (“Amendment”) to Form 8-K is being filed by Becton, Dickinson and Company (“BD”) to amend the Form 8-K filed by BD with the Securities and Exchange Commission (“SEC”) on August 5, 2021 (the “Original 8-K”). In the Original 8-K, BD reported that Christopher Reidy, the Executive Vice President, Chief Financial Officer (“CFO”) and Chief Administrative Officer (“CAO”) of BD, had announced his intention to retire from BD. Subsequent to the Original 8-K, BD reported that the Board of Directors of BD has elected Christopher DelOrefice as BD’s Executive Vice President and Chief Financial Officer, succeeding Mr. Reidy as BD’s CFO effective September 6, 2021. Upon Mr. DelOrefice joining BD, Mr.
Read the 8-K filing - Aug 11, 2021
On August 10, 2021, the Board of Directors of Becton, Dickinson and Company (“BD”) elected Christopher DelOrefice, 50, as BD’s Executive Vice President and Chief Financial Officer (“CFO”), effective September 6, 2021. As previously reported, Christopher R. Reidy, BD’s current CFO, has announced his intention to retire from BD. Mr. Reidy will continue to serve as BD’s Executive Vice President and Chief Administrative Officer following the effective date of Mr. DelOrefice’s election. BD is still in the process of finalizing a plan regarding Mr. Reidy’s transition responsibilities and the timing of his retirement. Mr. DelOrefice currently serves as Vice President, Investor Relations of Johnson & Johnson, and prior thereto, served as Johnson & Johnson’s Chief Financial Officer, North America Hospital Medical Devices, and as its Vice President Finance, North America. In connection with Mr.
Read the 8-K filing - Aug 5, 2021
On August 2, 2021, Christopher R. Reidy, Executive Vice President, Chief Financial Officer (“CFO”) and Chief Administrative Officer of BD informed BD of his intention to retire. Mr. Reidy will remain in his current role with BD until a successor is in place and will assist the new CFO in the transition. The Company is finalizing a plan that will include specific transition responsibilities and timing.
Read the 8-K filing - Jul 12, 2021
On July 12, 2021, Becton, Dickinson and Company (“BD”) announced that David F. Melcher and Claire Pomeroy, MD, MBA, both current BD board members, will join the board of directors of the company formed in connection with the previously announced separation of BD’s Diabetes Care business into an independent, publicly traded company (“NewCo”). Their appointments to the NewCo board of directors will be effective upon completion of the spinoff, which is expected to occur in the first half of calendar year 2022 and is subject to the satisfaction of customary conditions, including final approval from the BD board of directors and the effectiveness of a Form 10 registration statement that will be filed with the SEC.
Read the 8-K filing - Jan 28, 2021
On January 25, 2021, the Board of Directors of Becton, Dickinson and Company (“BD”) elected Thomas E. Polen, BD’s CEO and President, to the additional position of Chairman of the Board, effective April 28, 2021. Mr. Polen will succeed Vincent A. Forlenza as Chairman of the Board, and Mr. Forlenza will retire from BD upon the effectiveness of Mr. Polen’s election.
Read the 8-K filing - Nov 17, 2020
On November 13, 2020, Patrick K. Kaltenbach, Executive Vice President and President, Life Sciences Segment of Becton, Dickinson and Company (“BD”), informed BD that he plans to leave BD, effective January 21, 2021, to pursue an executive leadership position based in Europe, bringing him closer to his family. As previously announced, Dave Hickey, currently President of BD’s Integrated Diagnostics Solutions business unit, will succeed Mr. Kaltenbach as President, Life Sciences Segment, effective January 1, 2021. BD had previously announced plans to have Mr. Kaltenbach serve as BD’s Chief Technology Officer, beginning January 1, 2021. As a result of Mr.
Read the 8-K filing - Oct 22, 2020
The Board of Directors of Becton, Dickinson and Company (“BD”) has appointed Patrick K. Kaltenbach, currently BD’s Executive Vice President and President, Life Sciences Segment, to serve as BD’s Executive Vice President and Chief Technology Officer, effective January 1, 2021. David Hickey, who currently serves as President of BD’s Integrated Diagnostics Solutions business unit, will succeed Mr. Kaltenbach as President, Life Sciences Segment, also effective January 1, 2021.
Read the 8-K filing - Jan 31, 2020
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Sep 27, 2019
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Oct 3, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Aug 16, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Apr 25, 2018
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Sep 29, 2017
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Aug 11, 2017
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Apr 24, 2017
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Jul 29, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing - Jan 29, 2016
Director or officer change (Item 5.02). Open the filing for details.
Read the 8-K filing
Proxy statements (DEF 14A): 2025 · 2024 · 2023 · 2022 · 2021 · 2020
Share price
Annual financials
From the company's 10-K XBRL data (SEC companyfacts).
| Fiscal year | Revenue | Net income | Margin | Diluted EPS | Total assets |
|---|---|---|---|---|---|
| FY2025 | $21.8B | $1.7B | 7.7% | $5.82 | $55.3B |
| FY2024 | $20.2B | $1.7B | 8.4% | $5.86 | $57.3B |
| FY2023 | $19.4B | $1.5B | 7.7% | $4.94 | $52.8B |
| FY2022 | $18.9B | $1.8B | 9.4% | $5.88 | $52.9B |
| FY2021 | $19.1B | $2.1B | 10.9% | $6.85 | $53.9B |
| FY2020 | $16.1B | $874.0M | 5.4% | $2.71 | $54.0B |
| FY2019 | $17.3B | $1.2B | 7.1% | $3.94 | $51.8B |
| FY2018 | $16.0B | $311.0M | 1.9% | $0.60 | $53.9B |
Former directors and officers (40)
People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.